KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Total Current Liabilities (2016 - 2025)

Inovio Pharmaceuticals' Total Current Liabilities history spans 16 years, with the latest figure at $69.8 million for Q3 2025.

  • For Q3 2025, Total Current Liabilities changed N/A year-over-year to $69.8 million; the TTM value through Sep 2025 reached $69.8 million, changed N/A, while the annual FY2024 figure was $35.3 million, 17.02% down from the prior year.
  • Total Current Liabilities for Q3 2025 was $69.8 million at Inovio Pharmaceuticals, up from $31.7 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $131.1 million in Q2 2022 and bottomed at $26.4 million in Q2 2024.
  • The 5-year median for Total Current Liabilities is $51.7 million (2021), against an average of $58.1 million.
  • The largest annual shift saw Total Current Liabilities skyrocketed 153.27% in 2022 before it tumbled 60.38% in 2023.
  • A 5-year view of Total Current Liabilities shows it stood at $65.7 million in 2021, then soared by 47.35% to $96.9 million in 2022, then tumbled by 56.05% to $42.6 million in 2023, then decreased by 17.02% to $35.3 million in 2024, then soared by 97.66% to $69.8 million in 2025.
  • Per Business Quant, the three most recent readings for INO's Total Current Liabilities are $69.8 million (Q3 2025), $31.7 million (Q2 2025), and $35.3 million (Q4 2024).